CClinicalTrials.gg
RecruitingNCT07795502Updated Sep 1, 2026

Dynamic Infection Kinetics for Early Diagnosis, Monitoring, and Prognostication of Sepsis in Adult Oncology Patients: Evaluating Serial Infection Biomarkers, Blood Culture Kinetics, Treatment Response, Disease Severity, and Clinical Outcomes

An observational study in Sepsis, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Dynamic Infection Kinetics as an Early Diagnostic and Monitoring Tool for Sepsis in Oncology Patients

This study aims to evaluate whether changes over time in infection-related biomarkers and blood culture findings can help detect sepsis earlier and monitor the response to treatment in adult patients with cancer.

Cancer patients are at increased risk of developing serious infections and sepsis because of their underlying disease and its treatment. Early diagnosis and monitoring can be challenging because the signs and laboratory findings of infection may be nonspecific.

This prospective observational cohort study will include adult oncology patients with suspected sepsis who have at least one blood culture collected as part of their routine medical care. Clinical, laboratory, and microbiological information will be collected, including blood culture results, causative microorganisms, time to blood culture positivity, blood culture clearance time, C-reactive protein (CRP), procalcitonin (PCT), presepsin, absolute neutrophil count, serum lactate, and clinical severity measures.

Patients will be followed during hospitalization and for up to 30 days after enrollment. The study will assess whether changes in these markers over time are associated with treatment response, persistent infection, complications, intensive care admission, and mortality.

The findings may help identify patients at higher risk of poor outcomes and may contribute to improved monitoring and management of sepsis in patients with cancer.

02

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • Oncology patients
  • Early diagnosis
  • Infection kinetics
  • Procalcitonin
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult patients with solid or hematological malignancies who present with suspected sepsis and have at least one blood culture obtained as part of routine clinical care. Participants will be followed during hospitalization and for up to 30 days after enrollment to evaluate dynamic infection kinetics and clinical outcomes.

Inclusion criteria

  • Confirmed diagnosis of a solid or hematological malignancy.
  • Clinical suspicion of sepsis according to treating physicians.
  • At least one blood culture obtained before or shortly after initiation of antimicrobial therapy.
  • Availability for clinical follow-up during hospitalization.

Exclusion criteria

Exclusion Criteria:

  • Patients receive palliative care only.
  • Absence of blood culture sampling.
  • Incomplete clinical or laboratory data.
  • Refusal to participate in the study, when applicable.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Oncology Patients with Suspected Sepsis

    Adult oncology patients with suspected sepsis who have at least one blood culture obtained as part of routine clinical care. Participants will be followed during hospitalization and for up to 30 days after enrollment. Clinical, laboratory, and microbiological data will be collected to evaluate dynamic infection kinetics and their association with treatment response and clinical outcomes.

05

What researchers measure

Primary outcomes

  1. 30-day all-cause mortality

    Time frame: Within 30 days after enrollment

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to patient confidentiality and privacy considerations. Only aggregate study results will be reported.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07795502
Lead sponsor
Sohag University
Responsible party
Esraa Mohamed Abdelraheem (Demonstrator of Medical Microbiology & Immunology, Sohag University) — Principal investigator
First posted
Aug 31, 2026
Start date
Jul 15, 2026
Primary completion
Mar 7, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Sep 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion